학술논문
The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV:results from the EuroSIDA study
Document Type
Electronic Resource
Author
Source
Mocroft , A , Miro , J M , Wandeler , G , Llibre , J M , Boyd , A , van Bremen , K , Beniowski , M , Mikhalik , J , Cavassini , M , Maltez , F , Duvivier , C , Uberti Foppa , C , Knysz , B , Bakowska , E , Kuzovatova , E , Domingo , P , Zagalo , A , Viard , J-P , Degen , O , Milinkovic , A , Benfield , T , Peters , L , Kronborg , G , Gerstoft , J & The EuroSIDA Study Group 2022 , ' The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV : results from the EuroSIDA study ' , HIV Medicine , vol. 23 , no. 6 , pp. 585-598 .
Subject
Language
Abstract
Objectives: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH). Methods: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit. Results: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94–8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47–12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00–1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00–1.89) and NHL (aIRR 2.57; 95% CI 1.16–5.68). There was no significant association between HBV and lung or anal cancer. Conclusions: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.